Krystal Biotech, Inc. KRYS Return on assets
Return on assets at other companies
Other financials
Where this comes from
Calculated from Krystal Biotech, Inc.’s reported figures.
Based on trailing twelve months.
The official record: Krystal Biotech, Inc.’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →
Ask your AI about Krystal Biotech, Inc.'s return on assets.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Krystal Biotech, Inc.'s return on assets?
- Krystal Biotech, Inc. (KRYS) reported return on assets of 18.2% in Q1 2026.
- How has Krystal Biotech, Inc.'s return on assets changed year-over-year?
- Krystal Biotech, Inc.'s return on assets increased by 41.6% year-over-year, from 12.9% to 18.2%.
- What is the long-term trend for Krystal Biotech, Inc.'s return on assets?
- Over 5 years (2020 to 2025), Krystal Biotech, Inc.'s return on assets has grown at a 6.7% compound annual growth rate (CAGR), from -12.4% to 17.1%.
- What does return on assets mean?
- How much profit the company squeezes out of everything it owns.
- How do you interpret return on assets?
- Higher means more productive assets. Unlike ROE, it is unaffected by leverage, so a wide ROE-minus-ROA gap flags a heavily levered balance sheet.
- How does return on assets compare across companies?
- Best compared within an industry — asset intensity varies enormously across sectors. Not meaningful for banks, whose assets are largely financial.